Inhibition of Aβ42 aggregation using peptides selected from combinatorial libraries

Journal of Peptide Science

Volumn 15, Issue 8, 2009, Pages 499-503

  Baine, Michael ^a,b   Georgie, Daniel S ^a   Shiferraw, Elelta Z ^a   Nguyen, Theresa P T ^a,c   Nogaj, Luiza A ^a,d   Moffet, David A ^a  

^a LOYOLA MARYMOUNT UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Mount St Mary's College   (United States)

Author keywords

A 42; Alzheimer's disease; Amyloid inhibition; Peptide libraries; Thioflavin T

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ENHANCED GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; PEPTIDE LIBRARY; AMYLOID BETA PROTEIN; PEPTIDE; THIAZOLE DERIVATIVE; THIOFLAVINE;

ARTICLE; BACTERIAL COLONIZATION; ESCHERICHIA COLI; FLUORESCENCE; MICROBIAL DEGRADATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; METABOLISM; MOLECULAR GENETICS;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; DRUG EVALUATION, PRECLINICAL; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; THIAZOLES;

EID: 70349647479     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1150     Document Type: Article

References (36)

1. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo JS, Taddei N, Ramponi G, Dobson CM, Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002; 416: 507-511.
2. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006; 75: 333-366.
3. Murphy RM, Kendrick BS. Protein misfolding and aggregation. Biotechnol. Prog. 2007; 23: 548-552.
4. Calero M, Rostagno A, Frangione B, Ghiso J. Clusterin and Alzheimer's disease. Subcell. Biochem. 2005; 38: 273-298.
5. Lee S, Carson K, Rice-Ficht A, Good T. Hsp20, a novel alpha-crystallin, prevents Abeta fibril formation and toxicity. Protein Sci. 2005; 14: 593-601.
6. Santhoshkumar P, Sharma KK. Inhibition of amyloid fibrillogenesis and toxicity by a peptide chaperone. Mol. Cell. Biochem. 2004; 267: 147-155.
7. Yerbury JJ, Poon S, Meehan S, Thompson B, Kumita JR, Dobson CM, Wilson MR. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 2007; 21: 2312-2322.
8. Wilhelmus MMM,BoelensWC, Otte-Holler I, Kamps B, de Waal RMW, Verbeek MM. Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity. Brain Res. 2006; 1089: 67-78.
9. Smith TJ, Stains CI, Meyer SC, Ghosh I. Inhibition of beta-amyloid fibrillization by directed evolution of a beta-sheet presenting miniature protein. J. Am. Chem. Soc. 2006; 128: 14456-14457.
10. Robert R, Dolezal O, Waddington L, Hattarki MK, Cappai R, Masters CL, Hudson PJ, Wark KL. Engineered antibody intervention strategies forAlzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Eng. Des. Sel. 2009; 22: 199-208.
11. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005; 280: 5892-5901.
12. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity inAlzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 2003; 60: 1685-1691.
13. Ritchie CW, Bush AI, Masters CL. Metal-protein attenuating compounds and Alzheimer's disease. Expert Opin. Investig. Drugs 2004; 13: 1585-1592.
14. Wood SJ, MacKenzie L, Maleeff B, Hurle MR, Wetzel R. Selective inhibition of Abeta fibril formation. J. Biol. Chem. 1996; 271: 4086-4092.
15. Lashuel HA, Hartley DM, Balakhaneh D, Aggarwal A, Teichberg S, Callaway DJ. New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J. Biol. Chem. 2002; 277: 42881-42890.
16. Talaga P. Beta-amyloid aggregation inhibitors for the treatment of Alzheimer's disease: dream or reality?. Mini Rev. Med. Chem. 2001; 1: 175-186.
17. Cohen T, Frydman-Marom A, RechterM, Gazit E. Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry 2006; 45: 4727-4735.
18. Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des. 2006; 67: 27-37.
19. Porat Y, Mazor Y, Efrat S, Gazit E. Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. Biochemistry 2004; 43: 14454-14462.
20. Saengkhae C, Salerno M, Ades D, Siove A, Moyec L, Migonney V, Garnier-Suillerot A. Ability of carbazole salts, inhibitors of Alzheimer beta-amyloid fibril formation, to cross cellular membranes. Eur. J. Pharmacol. 2007; 559: 124-131.
21. Riviere C, Richard T, Quentin L, Krisa S, Merillon JM, Monti JP. Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro. Bioorg. Med. Chem. 2007; 15: 1160-1167.
22. Hull RL, Zraika S, Udaya-Sankar J, Kisilevsky R, Szarek WA, Kahn SE. Inhibition of islet amyloid formation in vitro by a small molecule inhibitor that reduces heparan sulfate proteoglycan (HSPG) synthesis. Diabetes 2006; 55: A372-a372.
23. Hamaguchi T, Ono K, Yamada M. Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. Cell. Mol. Life Sci. 2006; 63: 1538-1552.
24. Cherny RA, Atwood CS, Xilinas ME, Gray DN, JonesWD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, KimY, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30: 665-676.
25. Orner BP, Liu L, Murphy RM, Kiessling LL. Phage display affords peptides that modulate beta-amyloid aggregation. J. Am. Chem. Soc. 2006; 128: 11882-11889.
26. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. 1998; 4: 822-826.
27. Sato T, Kienlen-Campard P, Ahmed M, Liu W, Li H, Elliott JI, Aimoto S, Constantinescu SN, Octave JN, Smith SO. Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry 2006; 45: 5503-5516.
28. Esler WP, Stimson ER, Ghilardi JR, Felix AM, Lu YA, Vinters HV, Mantyh PW, Maggio JE. Abeta deposition inhibitor screen using synthetic amyloid. Nat. Biotechnol. 1997; 15: 258-263.
29. Blanchard BJ, Chen A, Rozeboom LM, Stafford KA, Weigele P, Ingram VM. Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc. Natl. Acad. Sci. U.S.A. 2004; 101: 14326-14332.
30. Wurth C,Guimard NK,Hecht MH.Mutations that reduce aggregation of the Alzheimer's Abeta42 peptide: an unbiased search for the sequence determinants of Abeta amyloidogenesis. J. Mol. Biol. 2002; 319: 1279-1290.
31. Wurth C, Kim W, Hecht MH. Combinatorial approaches to probe the sequence determinants of protein aggregation and amyloidogenicity. Protein Pept. Lett. 2006; 13: 279-286.
32. Kim W, Kim Y, Min J, Kim DJ, Chang YT, Hecht MH. A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. ACS Chem. Biol. 2006; 1: 461-469.
33. StemmerWPC, Crameri A, Ha KD, Brennan TM, Heyneker HL. Singlestep assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Gene 1995; 164: 49-53.
34. LeVine H, 3rd. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993; 2: 404-410.
35. Rogers DR. Screening for amyloid with the thioflavin-T fluorescent method. Am. J. Clin. Pathol. 1965; 44: 59-61.
36. Saeed SM, Fine G. Thioflavin-T for amyloid detection. Am. J. Clin. Pathol. 1967; 47: 588-593.